Koul et al. BMC Cancer 2010, 10:328 http://www.biomedcentral.com/1471-2407/10/328 Patent (PCT/IN09/000336) through Department of Bio- technology, Govt. of India. Acknowledgements This work was supported by core grant from DBT to the National Brain Research Centre, Manesar. DD, VS and NK are supported by a research fellowship from Council of Scientific and Industrial Research (CSIR, Government of India). The authors thank Mr Uttam Kumar Saini for technical assistance. Authors’ contributions VS and ES designed the research; NK, VS, DD and SG performed the experiments, VS and ES analyzed the data; ES wrote the paper. All authors read and approved the final version of the manuscript. Received: 5 January 2010 Accepted: 24 June 2010 Published: 24 June 2010 References 1. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797-1805. 2. Shao L, Lewin NE, Lorenzo PS, Hu Z, Enyedy IJ, Garfield SH, Stone JC, Marner FJ, Blumberg PM, Wang S: Iridals are a novel class of ligands for phorbol ester receptors with modest selectivity for the RasGRP receptor subfamily. Journal of medicinal chemistry 2001, 44(23):3872-3880. 3. Bonfils JP, Pinguet F, Culine S, Sauvaire Y: Cytotoxicity of iridals, triterpenoids from Iris, on human tumor cell lines A2780 and K562. Planta medica 2001, 67(1):79-81. 4. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996, 12(3):507-513. 5. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC: RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol- binding motifs. Science (New York, NY) 1998, 280(5366):1082-1086. 6. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer research 2001, 61(18):6674-6678. 7. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer cell 2007, 12(1):9-22. 8. Paternot S, Roger PP: Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer research 2009, 69(11):4577-4581. 9. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, et al: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine 2008, 5(1):e8. 10. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA: Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008, 14(11):3416-3426. 11. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB: A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer research 2007, 67(20):9630-9636. 12. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26(17):2435-2444. 13. Lo HW, Cao X, Zhu H, Ali-Osman F: Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High- Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators. Clin Cancer Res 2008, 14(19):6042-6054. 14. Zhu T, Tsuji T, Chen C: Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras. Oncogene 29(7):1050-1061. Page 7 of 8 15. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (New York, NY) 2009, 324(5935):1713-1716. 16. Oka M, Sumita N, Sakaguchi M, Iwasaki T, Bito T, Kageshita T, Sato K, Fukami Y, Nishigori C: 12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s). The Journal of biological chemistry 2009, 284(44):30416-30423. 17. Sharma V, Tewari R, Sk UH, Joseph C, Sen E: Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex. International journal of cancer 2008, 123(9):2204-2212. 18. Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, Sen E: HDAC inhibitor Scriptaid induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. Journal of cellular and molecular medicine 2009. 19. Sharma V, Joseph C, Ghosh S, Agarwal A, Mishra MK, Sen E: Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Molecular cancer therapeutics 2007, 6(9):2544-2553. 20. Dixit D, Sharma V, Ghosh S, Koul N, Mishra PK, Sen E: Manumycin inhibits STAT3, telomerase activity and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free radical biology & medicine 2009. 21. Kumar S, Lavin MF: The ICE family of cysteine proteases as effectors of cell death. Cell death and differentiation 1996, 3(3):255-267. 22. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS: Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer research 2003, 63(11):2742-2746. 23. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer cell 2006, 9(5):341-349. 24. Rajan P, Panchision DM, Newell LF, McKay RD: BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. The Journal of cell biology 2003, 161(5):911-921. 25. Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, et al: S9, a novel anticancer agent, exerts its anti- proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PloS one 2009, 4(3):e4881. 26. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000, 408(6811):433-439. 27. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, et al: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication- dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. The Journal of biological chemistry 2003, 278(22):20303-20312. 28. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes & development 1999, 13(18):2388-2399. 29. Ram R, Uziel O, Eldan O, Fenig E, Beery E, Lichtenberg S, Nordenberg Y, Lahav M: Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3- kinase/Akt pathway. Clin Cancer Res 2009, 15(3):914-923. 30. Zhou C, Gehrig PA, Whang YE, Boggess JF: Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Molecular cancer therapeutics 2003, 2(8):789-795. 31. Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH: Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer research 2005, 65(15):6516-6520. 32. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer research 2005, 65(17):7866-7873. 33. Schlessinger K, Levy DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer research 2005, 65(13):5828-5834. 34. Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67(1):156-158.